OncoMatch/Clinical Trials/NCT05070403
Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma
Is NCT05070403 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Afatinib 40 MG for squamous cell carcinoma.
Treatment: Afatinib 40 MG — The primary purpose of this study is to find out if Afatinib can help treat participants with advanced cSCC.
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-PD-1/PD-L1 therapy
Participants must have received prior immunotherapy with an anti-PD-1/PD-L1 antibody, if participant was deemed eligible (i.e., was not immunosuppressed or a transplant receipt, etc)
Lab requirements
Blood counts
ANC ≥ 1.0 × 10^9/L; Hemoglobin ≥ 8 g/dL; Platelets ≥ 75 × 10^9/L
Kidney function
Calculated creatinine clearance > 15mL/min by Cockroft-Gault formula
Liver function
AST and ALT ≤5 × ULN
Adequate bone marrow, organ function and laboratory parameters: ANC ≥ 1.0 × 10^9/L; Hemoglobin ≥ 8 g/dL; Platelets ≥ 75 × 10^9/L; AST and ALT ≤5 × ULN; Calculated creatinine clearance > 15mL/min by Cockroft-Gault formula
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Moffitt Cancer Center · Tampa, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify